anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Postamputation pain is currently managed unsatisfactorily with neuron-targeted pharmacological and interventional therapies. Non-neuronal pain mechanisms have emerged as crucial factors in the development and persistence of postamputation pain. Consequently, these mechanisms offer exciting prospects as innovative therapeutic targets. We examined the hypothesis that engaging mesenchymal stem cells (MSCs) would foster local neuroimmune interactions, leading to a potential reduction in postamputation pain. We utilized an ex vivo neuroma model from a phantom limb pain patient to uncover that the oligodeoxynucleotide IMT504 engaged human primary MSCs to promote an anti-inflammatory microenvironment. Reverse translation experiments recapitulated these effects. Thus, in an in vivo rat model, IMT504 exhibited strong efficacy in preventing autotomy (self-mutilation) behaviors. This effect was linked to a substantial accumulation of MSCs in the neuroma and associated dorsal root ganglia and the establishment of an anti-inflammatory phenotype in these compartments. Centrally, this intervention reduced glial reactivity in the dorsal horn spinal cord, demonstrating diminished nociceptive activity. Accordingly, the exogenous systemic administration of MSCs phenocopied the behavioral effects of IMT504. Our findings underscore the mechanistic relevance of MSCs and the translational therapeutic potential of IMT504 to engage non-neuronal cells for the prevention of postamputation pain. PERSPECTIVE: The present study suggests that IMT504-dependent recruitment of endogenous MSCs within severely injured nerves may prevent post-amputation pain by modifying the inflammatory scenario at relevant sites in the pain pathway. Reinforcing data in rat and human tissues supports the potential therapeutic value of IMT504 in patients suffering postamputation pain.
The invention relates to the field of traditional Chinese medicine application, and particularly discloses a traditional Chinese medicine composition used for treating conjunctivitis. The traditional Chinese medicine composition is composed of chrysanthemums, fructus viticis, pipewort, spina gleditsiae, paris polyphylla, rhizoma phragmitis, rhizoma pinelliae preparata, self heal, semen cassiae, nidus vespae, cynanchum paniculatum, zanthoxylum ailanthoides, stephania terandra, fructus kochiae and Chinese waxgourd seeds. The unique medicine properties of traditional Chinese medicine are utilized, and various types of pure traditional Chinese medicine supplement each other on the aspect of effect through dialectical medicine compatibility. The pharmacodynamic experiment verifies that the traditional Chinese medicine composition has the obvious effects on clearing heat, drying dampness, dispelling wind and removing nebula. No obvious adverse reaction is seen. The traditional Chinese medicine composition has the excellent performance of being simple in pharmacy, obvious in curative effect, small in side effects, convenient, safe and high in safety, has a good curative effect on conjunctivitis, and has quite good medical application prospects.
Currently there is no "best covering" or a standard "approved care" for treating partial thickness burns. Several options are available; however, they all have shortcomings. The application of topical antimicrobial dressings is time consuming and the regular dressing changes often associated with pain. Homograft or cadaver skin is often unavailable or in great shortage for skin transplants. Biobrane®, a biosynthetic wound dressing constructed of a silicone film with a nylon fabric partially imbedded into the film, has been available and used at our institute for many years as a skin substitute. It has been shown to reduce pain and the number of necessary dressing changes, and significantly reduced healing time (1). Its main side effects, although rare, are the occasional occurrence of infections and allergic reactions to the material.

Recently, a new product, AWBAT, has been developed for the coverage of partial thickness burns. AWBAT is similar to Biobrane® in terms of silicone membrane thickness, the structure of nylon fabric that gives the dermal substitute its strength, and the use of collagen peptides on the inner side of the membrane. These peptides are used for the purpose of reacting with the fibrin in the wound in order to achieve good initial adherence and to accelerate re-epithelialization. The key novelties of AWBAT are the different pore size and modality of collagen peptide attachments. These two key modifications aim at a reduction of the above mentioned adverse reactions.

The purpose of this study is to compare AWBAT to Biobrane® for covering partial thickness-burn injuries. We wish to determine if AWBAT, used in treating partial-thickness burns, would provide better healing, pain control, control of infection, shorter length of hospital stay, and improved scarring and long term recovery when compared to Biobrane®.
Systems and methods for managing physical location data and representation data in a health data dictionary. Clinical data is represented in a health data dictionary using a vocabulary that includes concepts and representations. Each concept is a unique item or idea and each concept can be associated with multiple representations. The default representations are difficult to use because most legacy systems are already accustomed to other terms or identifiers. The present invention allows the representations in the health data dictionary to be changed, altered, or modified according to the desires, of the legacy systems. The representation to be changed is identified by the legacy system and changed in accordance with instructions received from the legacy systems. The instructions may be to update, change, add, delete or otherwise modify a representation. The location manager is used to modify physical location data including representations, contexts, and concepts. The representation manager is used to modify contexts and representations of multiple types of data. In this manner, representations can be searched, assigned to other concepts, updated, changed, deleted, created and the like. The modules that perform these actions are subject to rules and constraints of the health data dictionary. Also, these modules modify relationships in the health data dictionary that are associated with the representations being changed.
This is a 49 weeks open-label,cluster randomized controlled study. Patients with schizophrenia and violence risk under the government supervision will be enrolled in the study. A community-based long-acting antipsychotics-treated management model will be applied to the experimental group, which means that professional psychiatrists will provide guidance to primary-level mental health workers on the psychotic treatment, and monthly-injected long-acting antipsychotic, paliperidone palmitate, will be used in the schizophrenia treatment. The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly per clinical judgement. For subjects who did not take risperidone, paliperidone extended release tablets, risperidone microspheres or paliperidone palmitate for injection previously, subjects should take oral paliperidone or risperidone sustained release tablets in the screening phase to perform ultra-sensitive test (the minimum dose of risperidone 1 mg/day and the minimum dose of sustained-release tablets paliperidone 3 mg/day, at least orally three days). Only subjects who were judged by the treating physician as tolerance to the drug could usepaliperidone palmitate .Suggest previous antipsychotics could be withdrawn within 4 weeks after first paliperidone palmitate administration , but will follow doctors' clinical judgement. The study protocol does not limit other medication or treatment measures except the injectable paliperidone palmitate. Other medication or treatment measures should be decided by doctors' clinical judgement and align with patients and caregivers.Subjects in control group will be treated and cared as usual.
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2, 6-difluorophenyl) methyl]-1H-1, 2, 3-triazole-4 carboxamide. It has an empirical formula of C10H8F2N4O and a molecular weight of 238.2. The drug substance is a white, crystalline, powder. Rufinamide is practically insoluble in water, slightly soluble in dimethylsulphoxide, tetrahydrofuran and in methanol, and very slightly soluble in ethanol and in acetonitrile. 

Rufinamide is available for oral administration as a liquid containing rufinamide at a concentration of 40 mg/mL. 

Inactive ingredients include Citric acid anhydrous, colloidal silicon dioxide , hydroxy ethyl cellulose, methyl paraben, microcrystalline cellulose/ carboxymethyl cellulose sodium, non-crystallizing sorbitol solution, orange juice, poloxamer 188, potassium sorbate, propyl paraben, propylene glycol, simethicone emulsion.
The invention belongs to the fields of genetic engineering and antibody medicines, and particularly relates to an anti-BAFF and hIL21 bispecific antibody and application thereof. The bispecific antibody comprising a first antigen-binding fragment that binds BAFF comprising a variable region CDR sequence of a belimumab monoclonal antibody and a belimumab-scFv single chain antibody variable region CDR sequence, and a second antigen-binding fragment that binds hIL21 comprising a variable region CDR sequence of a h18B10 monoclonal antibody; its Fc domain was obtained by a knob-into-hole mutation. The amino acid sequences of the heavy chain 1 and the heavy chain 2 of the bispecific antibody are respectively shown as SEQ ID NO.1 and SEQ ID NO.5, and the amino acid sequences of the light chain 1 and the light chain 2 are respectively shown as SEQ ID NO.3 and SEQ ID NO. 7. It can inhibit BAFF and IL21 simultaneously, and has synergistic effect in inhibiting overdose immune response. Therefore, the method has a certain prospect and value in preparing the therapeutic drugs for preventing, neutralizing and/or treating various autoimmune diseases related to the overexpression of BAFF and IL 21.
UDP-glucuronosyltransferases (UGT) Inducers

Concomitant use of UGT inducers decreases systemic exposure. Avoid the concomitant use of strong UGT inducers (e.g., rifampicin, phenytoin, phenobarbital, ritonavir). If you must administer JADENU tablets or JADENU Sprinkle granules with a strong UGT inducer, consider increasing the initial dose by 50%, and monitor serum ferritin levels and clinical responses for further dose modification [see Dosage and Administration (2.1, 2.2), Drug Interactions (7.5)].

Bile Acid Sequestrants

Concomitant use of bile acid sequestrants decreases systemic exposure. Avoid the concomitant use of bile acid sequestrants (e.g., cholestyramine, colesevelam, colestipol). If you must administer JADENU tablets or JADENU Sprinkle granules with a bile acid sequestrant, consider increasing the initial dose by 50%, and monitor serum ferritin levels and clinical responses for further dose modification [see Dosage and Administration (2.1, 2.2), Drug Interactions (7.6)].
Protein kinase D (PKD) enzymes play important roles in regulating myocardial contraction, hypertrophy, and remodeling. One of the proteins phosphorylated by PKD is titin, which is involved in myofilament function. In this study, we aimed to investigate the role of PKD in cardiomyocyte function under conditions of oxidative stress. To do this, we used mice with a cardiomyocyte-specific knock-out of Prkd1, which encodes PKD1 (Prkd1loxP/loxP; αMHC-Cre; PKD1 cKO), as well as wild type littermate controls (Prkd1loxP/loxP; WT). We isolated permeabilized cardiomyocytes from PKD1 cKO mice and found that they exhibited increased passive stiffness (Fpassive), which was associated with increased oxidation of titin, but showed no change in titin ubiquitination. Additionally, the PKD1 cKO mice showed increased myofilament calcium (Ca2+) sensitivity (pCa50) and reduced maximum Ca2+-activated tension. These changes were accompanied by increased oxidation and reduced phosphorylation of the small myofilament protein cardiac myosin binding protein C (cMyBPC), as well as altered phosphorylation levels at different phosphosites in troponin I (TnI). The increased Fpassive and pCa50, and the reduced maximum Ca2+-activated tension were reversed when we treated the isolated permeabilized cardiomyocytes with reduced glutathione (GSH). This indicated that myofilament protein oxidation contributes to cardiomyocyte dysfunction. Furthermore, the PKD1 cKO mice exhibited increased oxidative stress and increased expression of pro-inflammatory markers interleukin (IL)-6, IL-18, and tumor necrosis factor alpha (TNF-α). Both oxidative stress and inflammation contributed to an increase in microtubule-associated protein 1 light chain 3 (LC3)-II levels and heat shock response by inhibiting the mammalian target of rapamycin (mTOR) in the PKD1 cKO mouse myocytes. These findings revealed a previously unknown role for PKD1 in regulating diastolic passive properties, myofilament Ca2+ sensitivity, and maximum Ca2+-activated tension under conditions of oxidative stress. Finally, we emphasized the importance of PKD1 in maintaining the balance of oxidative stress and inflammation in the context of autophagy, as well as cardiomyocyte function.
Participants will be asked to reduce their daily eating time window to a maximum of 8 hours/day. They can choose when to begin their eating window but will be advised that the last meal should be completed before or at 20:00 hours. No calorie-containing food or beverage intake will be allowed outside the 8 hours eating window.
PURPOSE: Provided are an inhibitor of HIV-1 protease comprising, as an effective component, a peptide obtained by translating genetic information on the HIV-1 virus, and an analog; a method for preparing the same; and a pharmaceutical composition. CONSTITUTION: Provided is an inhibitor of HIV-1 protease comprising, as an effective component, a P2 peptide, which is a peptide obtained by translating genetic information on the HIV-1 virus. The inhibitor comprises, as an effective com served component, a synthesis peptide having the same amino acid sequence as that of the P2 peptide, or an analogous compound to the P2 compound. The inhibitor of HIV-1 protease of the present invention is basically a compound containing methionine, and may specifically be a peptide having an amino acid sequence comprising Ala-Glu-Ala-Met-Ser-Gln-Val-Thr-Asn-Thr-Ala-Thr-Ile-Met. A pharmaceutical composition, comprising a compound in a pharmacologically effective amount, and the compound is bonded to a pharmacologically acceptable salt. The method for preparing an inhibitor of HIV-1 protease, comprising finding a suicidal substance for inhibiting the HIV-1 protease from gene products of any HIV virus, and separating and purifying the substance to obtain the inhibitor of the HIV-1 protease.
Intestinal ischemia-reperfusion injury (IIRI) is a serious disease with high morbidity and mortality. This study aims to investigate the potential regulatory mechanisms involving protein arginine methyltransferase 6 (PRMT6), Forkhead box O3a (FoxO3a), and Parkin in IIRI and elucidate their roles in mediating cell apoptosis. The IIRI animal model was established and confirmed using hematoxylin and eosin staining. Oxygen-glucose deprivation and reperfusion (OGD/R) cell model was established to mimic ischemic injury in vitro . Transient transfection was used to overexpress or knock down genes. Cell death or apoptosis was assessed by propidium iodide staining, terminal deoxynucleotidyl transferase dUTP nick end labeling assay, and flow cytometry. The expression of proteins was detected by western blot. The histopathology observed by hematoxylin and eosin staining suggested that the IIRI animal model was successfully established. Our findings revealed that IIRI resulted in increased Bax and decreased Bcl-2 levels. In vitro experiments showed that overexpression of Parkin decreased OGD/R injury and suppressed elevation of Bax/Bcl-2. PRMT6 regulated the methylation level of FoxO3a. Moreover, FoxO3a directly binds to Parkin, and FoxO3a overexpression reduced OGD/R-induced cell death and regulation of Parkin. Overexpression of PRMT6 can attenuate the downregulation of Parkin and elevation of Bax/Bcl-2 caused by OGD/R. Knockdown of PRMT6 promoted apoptosis in intestinal epithelial cells of OGD/R group, while PRMT6 overexpression exhibited the opposite effect. Notably, the levels of PRMT6, FoxO3a, and Parkin were decreased in IIRI mouse intestinal tissue. Knocking out PRMT6 causes a significant decrease in the lifespan of mice. Altogether, our results demonstrated that PRMT6 upregulated the expression of Parkin by regulating FoxO3a methylation level, attenuating the apoptosis induced by IIRI.
Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
PURPOSE:The titled controlling agent prepared by joining a leachate obtained from Euchresta japonica Benth., Sophora angustifolia (Sophorae Radix) and Glycyrrhiza glabra L. var. glandulifera Regel et Herder (licorice) to a leachate obtained from a fruit of Opuntia Brasiliensis Haw., Opuntia arborescens Eng., etc., boiling and cooling the resultant mixture, filtering the cooled mixture, and adding L-histidine, etc. to the filtrate. CONSTITUTION:A controlling agent against flachery diseases of silkworms prepared by joining a leachate obtained by dipping Euchresta japonica Benth. (the root of the Euchresta japonica Benth. or the root dried in the shade), Sophora angustifolia (the root of the Sophora angustifolia or the root dried in the shade; Sophorae Radix) and Glycyrrhiza glabra L. var. glandulifera Regel et Herder (licorice) in hot water to a leachate obtained by dipping a fruit of Opuntia Brasiliensis Haw., Opuntia arborescens Eng., etc. in warm water, and if necessary boiling the resultant mixture, cooling the mixture, filtering or centrifuging the mixture with a centrifugal separator, and adding L-histidine and/or L-ascorbic acid to the resultant filtrate, etc. The Euchresta japonica Benth. and Sophora angustifolia (Sophorae Radix) contain matrine and oxymatrine as principal components, and the Sophora angustifolia contains further sophoranol, anagyrine, isomatrine, etc. as accessory components.
Background: To improve care of geriatric trauma patients, the American College of Surgeons (ACS) Trauma Quality Improvement Program (TQIP) updated guidelines in 2021. Amid geriatrician shortages in Southern California, 2 Los Angeles County safety net hospitals were tasked with creating a strategy to meet geriatric trauma guidelines despite constrained resources. Methods: All trauma patients ≥ 60 years admitted to a safety net hospital in Southern California were enrolled without exclusions (August 2022-April 2023). Primary outcome was frailty screening with documentation to identify older trauma patients at a high risk for adverse outcomes. Results: Needs assessment discovered no standardized process to identify high-risk geriatric patients, no geriatric care guidelines, and no inpatient geriatric consultation service. An action plan composed of a resident-led frailty screen resulted in identification of high-risk patients. Overall, 217 patients met criteria. Ninety-six patients (44%) successfully underwent frailty screening. Frailty screening compliance increased over the study, beginning at 37% capture in the first month and increasing to 81% in the final study month. After achieving nearly uniform frailty screening, a form was developed for the EMR for ease of documentation, data capture/tracking, and compliance monitoring. Discussion: In this study, creativity, collaboration, and resourcefulness allowed TQIP guideline implementation at 2 county hospitals. A systematic process is now in place to identify and triage high-risk geriatric trauma patients based on frailty screen to receive inpatient medicine consultation for medical comorbidity optimization. Continued interdisciplinary and interfacility collaboration will be crucial for continued delivery of the optimal care to older injured patients.
PURPOSE:To obtain an external drug for skin, by using an extract of water-soluble blueberry as an active component and adding a sugar alcohol as a stabilizer. CONSTITUTION:Fruit of wild or cultured blueberry is crushed and extracted with water or a water-soluble solvent. The extracted liquid is concentrated and dried to obtain an extract of water-soluble blueberry component as dark reddish purple powder. The objective external drug for skin is produced by using the blueberry component as an active component and adding a sugar alcohol (a polyhydric alcohol produced by reducing carbonyl group of a sugar molecule; e.g. sorbitol, mannitol, maltitol, etc.) as a stabilizer in an amount of >=5wt% based on the whole composition. The stability of the agent can be further improved by acidifying the agent to 3-6 pH with an organic acid (e.g. citric acid, lactic acid, etc.) or its salt or by using an antioxidant such as sodium sulfite, etc. The agent may be used in combination with cosmetics or various other drugs.
After the transfemoral angiography procedure, the patient will be taken to bed and monitored. Approximately 2 hours after the procedure, under the control of the doctor and nurse, the sheath in the patient's groin area will be pulled and a 3 kg sandbag will be left. A 36x33x10 cm gel-containing visco pillow will be placed in the patient's lumbar cavity by the research nurse and primary nurse to fill the anatomical space. The patient will be monitored in a supine position with the head elevated (30 degrees) and blood pressure, pulse, respiratory rate, oxygen saturation and comfort and pain level will be recorded at 0, 3 and 6 hours.
The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Intervention group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form. These exercises were not given to the control group.
PURPOSE: A tacrolimus formulation and a method for manufacturing the same are provided to quickly increase solubility and bioavailability of tacrolimus. CONSTITUTION: A tacrolimus microparticle contains a solid particulate substrate and tacrolimus layer in which tacrolimus is dispersed in a soluble polymer carrier. The carrier is hydroxypropyl methylceullose(HPMC), polyvinylpirrolydone(PVP), cellulose polymer or mixture thereof. The solid particlulate substrate is beads, spheres, cores, seeds, particles, or nuclei. The tacrolimus microparticle is obtained by dissolving HPMC and tacrolimus in mixture solvent of organic solvent and water. An oral formulation contains the tacrolimus microparticle. The oral formulation is a capsule or tablet.